Predictive Value of Venous Excess Ultrasound Score in Management of Cardiorenal Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-01

Study Completion Date

2024-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess predictive value of venous excess ultrasound score in cardiorenal patient management

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment According to Venous Excess Ultrasound Score in Patients With Heart Failure

NCT06341816

Heart Failure Acute Kidney Injury

NOT_YET_RECRUITING NA

Prevalence of Venous conGestion and Its Association With Renal Injuries Evaluated by the VExUS Score On Admission With UltraSound in Patients With Cardiogenic Pulmonary Edema

NCT05881603

Cardiogenic Acute Pulmonary Edema

UNKNOWN

VExUS in Ards Patients and Association with AKI

NCT06805409

Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

RECRUITING

Portable Ultrasound to Predict Heart Failure Readmission Risk

NCT05980533

Heart Failure Patient Readmission

WITHDRAWN NA

VExUS Combined With CVP to Predict Clinical Outcomes in Sepsis Participants

NCT06524622

Sepsis Acute Kidney Injury

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cardiorenal syndrome encompasses a spectrum of disorders involving both the heart and kidneys in which acute or chronic dysfunction in 1 organ may induce acute or chronic dysfunction in the other organ.

Fluid overload is deleterious in critically ill patients; apart from increased mortality, it can cause end-organ damage, thereby increasing the incidence of acute kidney injury (AKI), length of stay in ICU, and duration of mechanical ventilation.

Elevation of central venous pressure is directly transmitted to the renal veins because venous vascular resistance is negligible. As the encapsulated kidney has little room to expand, venous congestion causes renal interstitial hydrostatic pressure to increase. Furthermore, as the post-glomerular vascular and tubular network is a low-pressure system , the increase in the renal interstitial pressure causes compression or even occlusion of renal tubules. That in turn results in reduction or even shut down of tubular flow and shut down in the glomerular filtration .

The venous excess ultrasound (VExUS) score incorporates hepatic venous, intrarenal venous Doppler, inferior vena cava (IVC) assessment, and portal vein Doppler. By utilizing multiple parameters, the negative aspects of individual parameters might get negated and could be considered as a reliable tool to assess congestion of kidneys.

The investigators hypothesise that VExUS score could be valuable in predicting cardiorenal patients who need ultrafiltration in ICU. In this study the investigators will use VEXSUS score to predict response to diuretic therapy, to evaluate patients' volume status, and to predict mortality in cardiorenal patient

Every patient will be subjected to

1. Medical history taking.
2. Complete physical examination.
3. Routine laboratory investigations including baseline urea, creatinine, electrolytes, urine analysis, complete blood count, coagulation profile, liver functions test, arterial blood gas, serum lactate and daily follow up urea, creatinine, and electrolytes.
4. ECG, echocardiography, and lung ultrasound.
5. Volume status will be assessed by urine output, CVP, mean arterial pressure.
6. The following work up.

* VExUS score (IVC assessment, hepatic venous, intrarenal venous Doppler and portal vein Doppler)
* Cardiorenal patient will receive diuretic therapy as a standard treatment in patients with VEXSUS score 1-3
* Daily VExUS score will be done
* Diuretic resistance will be defined as failure to produce 0.5 ml/kg/h of urine after administration of at least double the dose of the patient's home diuretic therapy or after administration of 250 mg of Lasix and 10 mg of Metolazone in diuretic naïve patient).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardio-Renal Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VExUS score

The venous excess ultrasound (VExUS) score incorporates hepatic venous, intrarenal venous Doppler, inferior vena cava (IVC) assessment, and portal vein Doppler

Intervention Type OTHER

Diuretic Effect

Response to diuretic therapy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with congestive heart failure and GFR less than 100 ml/minute

Exclusion Criteria

* Patients below 18 years old. Patients with liver cirrhosis and portal hypertension. Patients with IVC thrombus. Patients with inadequate ultrasonography window.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No